Sanofi has
been presented with an award from the 2012 Thomson Reuters Extel Survey in
recognition of its high standard of investor relations.
The company earned the accolade of leading pan-European quoted company for investor relations, while also topping the European pharmaceuticals and biotechnology sector rankings for the third consecutive year.
The company earned the accolade of leading pan-European quoted company for investor relations, while also topping the European pharmaceuticals and biotechnology sector rankings for the third consecutive year.
Considered the leading benchmark for excellence in investor relations, the survey is compiled using contributions from more than 14,000 professionals, with all data verified by professional services company Deloitte.
Sanofi has ascended the list of top pan-European quoted companies rapidly since debuting at 35th place in 2009, coming fifth in 2010 and second last year.
Christopher Viehbacher, chief executive officer at Sanofi, said: "Our award recognises the high-quality dialogue between the company and the financial community and underscores Sanofi's commitment to excellence in investor relations."
According to the firm's most recent fiscal report, Sanofi experienced sales growth of 9.4 percent during the first quarter of 2012, thanks primarily to the positive impact of last year's Genzyme takeover.
